A 32-year-old man from rural Maharashtra presents with a 3-month history of productive cough, fever, and night sweats. Chest X-ray shows cavitary lesions in the right upper lobe. Sputum smear microscopy is positive for acid-fast bacilli. He is started on standard 4-drug anti-TB regimen (HRZE). After 2 months of therapy, repeat sputum smear remains positive. On further questioning, he admits to irregular drug intake due to side effects. What is the most appropriate next step in management?

Explanation

## Clinical Assessment This patient has **sputum smear positivity at 2 months** of standard 4-drug anti-TB therapy (HRZE), but crucially, he **admits to irregular drug intake** due to side effects. This is a critical distinction in TB management. ## Management Algorithm for Sputum Positivity at 2 Months ``` Sputum positive at 2 months ↓ Is adherence adequate? ↙ ↘ NO YES ↓ ↓ Reinforce Suspect drug resistance adherence → Send CBNAAT/DST counselling → Consider 2nd-line therapy Continue HRZE ``` ## Key Point: **As per RNTCP/National TB Elimination Programme (NTEP) 2023 guidelines**, the management of sputum positivity at 2 months depends critically on the **reason for failure**: 1. **If due to poor adherence** (as in this case): The correct step is to **reinforce adherence counselling, address side effects, and continue the same HRZE regimen** for the full 6-month course. Switching to second-line drugs prematurely in a non-adherent patient risks creating further resistance. 2. **If adherence is confirmed adequate**: Suspect drug resistance → send sputum for CBNAAT/GeneXpert (rapid rifampicin resistance detection) and culture + DST → initiate second-line therapy based on results. ## Why Option D is Incorrect: Adding a 5th drug (ethionamide) empirically in a patient whose failure is attributable to **documented non-adherence** is not recommended. This approach is reserved for confirmed or highly suspected drug-resistant TB where adherence has been adequate. Empirical addition of second-line drugs in a non-adherent patient risks amplifying resistance to second-line agents as well. ## Why Option A is Incorrect: Stopping all anti-TB drugs is dangerous and not recommended. It risks disease progression and resistance amplification. ## Why Option C is Incorrect: Switching to a 2-drug regimen (HR) is never appropriate in active TB with sputum positivity — this constitutes functional monotherapy and is a major driver of MDR-TB. ## High-Yield: - **NTEP/RNTCP 2023**: Sputum positivity at 2 months with documented non-adherence → reinforce adherence, manage side effects, continue HRZE for full 6 months - **CBNAAT/GeneXpert** is indicated when drug resistance is suspected (adequate adherence + persistent positivity), not automatically for all 2-month failures - Irregular adherence is the **most common cause of treatment failure** in India; addressing it is the first step ## Clinical Pearl: The distinction between **treatment failure due to non-adherence** vs. **true drug resistance** is fundamental. NTEP guidelines explicitly state that in patients with documented poor adherence, the priority is adherence support and continuation of the current regimen — not empirical escalation to second-line drugs. [cite: NTEP/RNTCP Guidelines 2023; Harrison's Principles of Internal Medicine 21e, Ch. 165]